BYSI BeyondSpring

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.

BYSI stock data


Press releases

From Benzinga Pro
BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors
21 Oct 21
—The study is conducted by the Big Ten Cancer Research Consortium in up to 26 patients across 7 states in the U.S. —In the Phase 1 study, plinabulin combination was able to induce tumor responses in patients who had
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference to Further Support the Positive Clinical Data Already Reported for the Treatment of Small Cell Lung Cancer
20 Oct 21
Plinabulin's anti-cancer effects were tested against approximately 80 patient-derived tumor models with small cell lung cancer (SCLC) tumor types being the most sensitive to plinabulin monotherapy at IC70 of 35 nMThe
BeyondSpring Pharmaceuticals Announces Positive Final Phase 3 DUBLIN-3 Data with the Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line Non-Small Cell Lung Cancer Patients with EGFR Wild Type at the European Society for Medical Oncology (ESMO) 2021 Congress
20 Sep 21
Study met the primary endpoint showing statistically significant improvement in overall survival (OS) for the combination (DP) vs. docetaxel (D).Study met key secondary endpoints showing statistically significant
BeyondSpring Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
10 Sep 21
BeyondSpring to Participate in the Upcoming September Conferences
8 Sep 21

Investment data

Data from SEC filings
Securities sold
Number of investors


30 Apr 21
26 Oct 21
31 Dec 21
Quarter (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 109.54M 109.54M 109.54M 109.54M 109.54M 109.54M
Cash burn (monthly) (positive/no burn) (positive/no burn) 6.21M 4.05M 2.32M 2.33M
Cash used (since last report) n/a n/a 61.17M 39.94M 22.88M 22.97M
Cash remaining n/a n/a 48.36M 69.6M 86.66M 86.56M
Runway (months of cash) n/a n/a 7.8 17.2 37.3 37.1

Beta Read what these cash burn values mean

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

36.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 61 66 -7.6%
Opened positions 11 14 -21.4%
Closed positions 16 12 +33.3%
Increased positions 27 28 -3.6%
Reduced positions 20 13 +53.8%
13F shares
Current Prev Q Change
Total value 162.63M 181.72M -10.5%
Total shares 14.06M 13.65M +3.0%
Total puts 82.5K 10.8K +663.9%
Total calls 93K 45.3K +105.3%
Total put/call ratio 0.9 0.2 +272.1%
Largest owners
Shares Value Change
Ever Regal 4.62M $56.36M 0.0%
Alliancebernstein 3.01M $31.41M +17.3%
Decheng Capital China Life Sciences USD Fund III 1.98M $20.21M 0.0%
BLK Blackrock 1.42M $14.81M +16.6%
Blair William & Co 430.58K $4.5M +82.7%
STT State Street 308.86K $3.23M +0.6%
NTRS Northern Trust 217.72K $2.27M +8.9%
Geode Capital Management 198.09K $2.07M +14.9%
Tanaka Capital Management 197.44K $2.06M +123.0%
Discovery Capital Management, LLC / CT 172.7K $1.8M -35.6%
Largest transactions
Shares Bought/sold Change
Alliancebernstein 3.01M +443.05K +17.3%
BLK Blackrock 1.42M +202.06K +16.6%
Blair William & Co 430.58K +194.93K +82.7%
Driehaus Capital Management 0 -125K EXIT
Renaissance Technologies 0 -123.8K EXIT
Tanaka Capital Management 197.44K +108.89K +123.0%
Discovery Capital Management, LLC / CT 172.7K -95.6K -35.6%
Altshuler Shaham 83.69K +83.69K NEW
Marshall Wace 128.12K -64.44K -33.5%
Citadel Advisors 102.51K +62.69K +157.4%

Financial report summary

Content analysis
H.S. sophomore Avg
New words: AACR, Abbott, Abscopal, accretion, aggressive, agile, agonist, akin, Albany, AllianceBernstein, Altimmune, altogether, antigen, Asymchem, attack, BCF, benchmarking, Biden, bifurcated, bifurcation, Biochemical, Black, bladder, BofA, boost, boosting, break, BSHI, built, campaign, cascade, CCE, Chairperson, Chapter, Chase, chemo, chose, CI, Citibank, Clayton, COA, Coagulo, constraint, Covance, criterion, crucial, CSRC, CTRL, Czerepak, DelCath, dismissed, dissolution, Duhnke, durable, dysfunctional, Edoc, Eleventh, Elizabeth, embedded, essence, Evercore, EVP, familiar, feature, fifteen, FINRA, Fintech, floating, forecasting, Forty, Foundation, fractionated, Francisco, freestanding, FT, gas, Genevant, George, GmbH, harnessing, hazard, heard, heightened, hematologist, hierarchical, highlighted, highlighting, histocompatibility, hit, honored, host, HR, Hudson, Humanitarian, Hutch, hybrid, Immunomodulating, infusion, inquiry, intraperitoneal, involuntary, IQVIA, iron, irradiated, Isarna, Island, JAMA, Jay, JP, Kashyap, Kennedy, kill, Knoll, Kolliphor, La, lab, Lancet, legacy, lesion, LIAC, Lin, Majeti, Marshall, Master, Matthey, maximize, MBA, Media, Merkle, mezzanine, Micro, microsatellite, mission, move, moved, Mt, municipal, nadir, NASD, neoantigen, Newsday, NYSE, Nyvepria, OCA, Odonate, oncologist, OneOncology, onset, ORR, overtime, paper, participatory, passion, patentee, Paycheck, penalize, Pfizer, PFS, Pii, Plin, postponed, predictor, profound, prolong, punitive, PWG, radiotherapy, Ravindra, ready, Red, Roosevelt, rulemaking, Sala, SAMR, save, Scilex, screening, shorter, shrinkage, SIMBA, Sinai, sixty, solved, SPA, Spectrum, St, Steven, stewardship, strongly, sublicense, systematical, tariff, TCFA, TEAE, Theodore, thereon, tiered, topline, tort, TPD, TTEE, turn, Twelfth, Tyrokine, Ub, underscored, undruggable, unlocking, unobservable, upcoming, Urban, vaccine, Vacirca, Valley, waiver, war, wave, weak, Westchester, window, worse, worth
Removed: acute, admit, allot, arose, attending, bachelor, bevacizumab, caption, carryforward, CEO, certainty, chemotoxic, communicating, constituent, consummation, coursework, deprived, differentiated, discontinue, disorder, downstream, ending, enlarged, Epiphron, extracted, facilitating, finalization, fourth, gather, guanine, hematological, hour, Hutchinson, intragroup, Lynch, marking, Mattey, Merrill, nonresident, nucleotide, observation, predicted, privately, programmed, recruited, reject, rental, respiratory, restart, restarted, Revision, selectively, seller, senile, sickle, signal, Solutol, spleen, structured, Switzerland, syndrome, taxing, template, tolerated, transduction, Tsinghua, ultrasonic, unconsolidated, vascularized, waiting, Yale


No filings